Individual Patient Compassionate Use of Fedratinib

Celgene

Overview

This is an expanded access program (EAP) for eligible participants designed to provide access to fedratinib. Expanded access is only available in markets where fedratinib is not yet approved.

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.

Study Type

EXPANDED_ACCESS

Conditions

Myelofibrosis

Interventions

Oral FedratinibDRUG

Oral fedratinib administered as directed by treating physician.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Subjects will be considered if they received TG101348, SAR302503 or Fedratinib as a participant on a clinical trial prior to 31 Jan 2018. Exclusion Criteria: Subject is eligible for enrollment in an ongoing clinical trial using Fedratinib or has been treated with Fedratinib after 31 Jan 2018.

Locations (1)

Celgene

Summit, New Jersey, United States

AVAILABLE

Central Contacts

Celgene Medical Information

CONTACT

1-888-771-0141 medinfo@celgene.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.